Alexander M. Lesokhin

Author

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

A Lesokhin, A. Lesokhin, A. M. Lesokhin, A.M. Lesokhin, Alex Lesokhin, Alex M. Lesokhin, Alexander Lesokhin, Alexander M Lesokhin, Alexander M. Lesokhin

547

Publications

24K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University Harvard University Dana-Farber Cancer Institute Massachusetts General Hospital

About

Alexander M. Lesokhin is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	42	6.5K
2	Health Sciences	17	25	3.2K
3	Public Health	1	1	17
4	Allergy	1	1	15
5	Biology	1	1	120

Alexander M. Lesokhin

126

Publications

22K

Citations

H-Index

Page 1

	Year	Citations
Nivolumab plus Ipilimumab in Advanced Melanoma Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan, New England Journal of Medicine	2013	4.2K
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello, New England Journal of Medicine	2014	3.5K
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma Michael A. Postow, Margaret K. Callahan, Christopher A. Barker, New England Journal of Medicine ImmunologyPathologyDermatologyImmune SystemImmunotherapy	2012	2K
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani, The Lancet Hematological MalignancyCell TherapyImmunotherapyCiltacabtagene AutoleucelMedicine	2021	1.5K
Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy Jarushka Naidoo, Xuan Wang, Kaitlin M. Woo, Journal of Clinical Oncology	2016	1.1K
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study Alexander M. Lesokhin, Stephen M. Ansell, Philippe Armand, Journal of Clinical Oncology	2016	1K
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up Thomas G. Martin, Saad Z. Usmani, Jesús G. Berdeja, Journal of Clinical Oncology	2022	580
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results Alexander M. Lesokhin, Michael H. Tomasson, Bertrand Arnulf, Nature Medicine Hematological MalignancyMagnetismm-3 Trial ResultsMedicineBispecific AntibodySubcutaneous Elranatamab	2023	483
GPRC5D-Targeted CAR T Cells for Myeloma Sham Mailankody, Sean M. Devlin, Jonathan Landa, New England Journal of Medicine	2022	367
Monocytic CCR2+ Myeloid-Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T-cell Infiltration into the Tumor Microenvironment Alexander M. Lesokhin, Tobias M. Hohl, Shigehisa Kitano, Cancer Research	2011	363

Page 1